AbbVie has built one of the most impressive dividend growth records in the pharmaceutical sector. The company has increased its dividend every year since splitting from Abbott Laboratories in 2013, and the yield remains among the highest in the large-cap healthcare space. For income investors, the question is whether AbbVie can sustain that growth now that its blockbuster drug Humira has lost patent protection.
The setup: AbbVie’s transition beyond Humira
Humira was the world’s best-selling drug for nearly a decade, generating more than $20 billion in annual peak sales for AbbVie. The biologic immunology treatment accounted for a significant portion of company revenue and profits. When biosimilar competition entered the U.S. market in 2023, AbbVie faced a steep revenue cliff that threatened its dividend growth trajectory.
The company prepared for this transition by building a pipeline of newer immunology drugs, including Skyrizi and Rinvoq. Both products have shown strong uptake and are expected to offset a substantial portion of the Humira revenue decline. AbbVie also expanded through acquisitions, most notably the $63 billion purchase of Allergan in 2020, which added the Botox franchise and diversified the revenue base.
Key numbers for AbbVie investors
| Metric | Value |
| Current quarterly dividend | $1.64 per share |
| Annual dividend yield | 3.4% – 3.7% |
| Consecutive years of dividend increases | 11+ (since 2013 spinoff) |
| Payout ratio | 50% – 55% |
| 5-year dividend CAGR | 8.5% |
| Shares per $100,000 invested | ~520 |
| Annual income per $100,000 | ~$3,400 – $3,700 |
Peer comparison: ABBV vs other healthcare dividend stocks
| Company | Ticker | Yield | Years of Growth | Payout Ratio |
| AbbVie | ABBV | 3.5% | 11+ | 52% |
| Johnson & Johnson | JNJ | 3.0% | 62 | 45% |
| Pfizer | PFE | 5.8% | 15 | 95% |
| Merck | MRK | 2.6% | 14 | 48% |
What to watch: Pipeline and patent risks
The most important variable for AbbVie investors is the rate at which Skyrizi and Rinvoq can replace Humira revenue. Both drugs have shown strong clinical data and are gaining market share in psoriasis, Crohn’s disease, and ulcerative colitis. However, biosimilar competition for these products will eventually arrive, and AbbVie will need to demonstrate that its pipeline can continue delivering new blockbusters.
The Allergan acquisition added complexity to the balance sheet. AbbVie took on significant debt to complete the deal, and interest expense has risen with higher rates. The company has been paying down that debt, but any slowdown in cash flow generation could delay deleveraging plans and put pressure on the dividend growth rate.
Patent litigation is another ongoing risk. AbbVie has faced multiple lawsuits related to Humira pricing and patent strategies. While these cases are unlikely to threaten the dividend directly, adverse rulings could result in significant payments or reputational damage that affects the stock price.
Common mistakes income investors make with ABBV
Some investors assume that AbbVie’s high yield makes it a safer income play than lower-yielding healthcare stocks. In reality, the yield reflects the Humira patent cliff risk and the company’s dependence on a small number of high-revenue drugs. A 3.5 percent yield is attractive, but it comes with concentration risk that more diversified healthcare companies do not face.
Another mistake is ignoring the patent timeline. Investors who buy AbbVie without understanding the Humira decline and the Skyrizi ramp are making a bet on a specific product transition. That transition has gone well so far, but pharmaceutical pipelines are unpredictable. A clinical setback for a key drug could change the outlook rapidly.
Finally, some retirees overallocate to healthcare stocks in general, believing the sector is defensive. While healthcare does have defensive characteristics, individual pharmaceutical companies carry significant patent and regulatory risks. A diversified sector approach is safer than concentrating in one or two names.
Analyst outlook for AbbVie
Analysts at UBS maintain a “Buy” rating on ABBV with a price target of $210. They believe Skyrizi and Rinvoq will exceed $20 billion in combined annual sales by 2027, effectively replacing the Humira revenue base. BMO Capital Markets assigns a fair value estimate of $195, noting that the company’s neuroscience pipeline adds optionality beyond immunology.
Morgan Stanley analysts caution that the pace of dividend growth may slow from the historical 8 to 10 percent range to 4 to 5 percent annually as the company invests in new product launches and continues deleveraging. They still view the dividend as secure given the payout ratio and cash flow generation.
The consensus view among surveyed firms suggests AbbVie is a hold for conservative income investors and a buy for those with a moderate risk tolerance who understand the product transition dynamics. The yield is above the sector average, but the business model is more concentrated than peers like Johnson & Johnson.
Bottom line
AbbVie offers one of the highest yields among large-cap healthcare stocks with a dividend growth record that is still building. The transition from Humira to Skyrizi and Rinvoq has progressed better than many expected, and the payout ratio remains comfortable. However, the company’s reliance on a narrow portfolio of high-revenue drugs creates concentration risk that conservative investors should not ignore. ABBV fits best as a higher-yield satellite position within a diversified healthcare allocation.
Stay ahead with our weekly newsletter
Get stock picks, market analysis, and strategy updates delivered to your inbox every week.
Subscribe to AlphaBetaStock’s free newsletter for daily market insights.
